STEAP1: a promising target in prostate cancer therapy

Rohit Singh; Jon Amund Kyte

doi:10.1016/j.trecan.2025.05.007

STEAP1: a promising target in prostate cancer therapy

Trends Cancer. 2025 Jun 16:S2405-8033(25)00141-4. doi: 10.1016/j.trecan.2025.05.007. Online ahead of print.

Authors

Rohit Singh¹, Jon Amund Kyte²

Affiliations

¹ Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway.
² Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway; Department of Clinical Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway; Faculty of Health Sciences, Oslo Metropolitan University, 0166 Oslo, Norway. Electronic address: jonky@ous-hf.no.

PMID: 40527692
DOI: 10.1016/j.trecan.2025.05.007

Abstract

The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.

Keywords: CAR-T cell; STEAP1; T cell engagers; antibody drug conjugates; immunotherapy; metastatic castration-resistant prostate cancer.